[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354082-105":59,"doc-detail-354082-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-advances-in-preclinical-patient-derived-cultivation-models-for-individualized-drug-response-prediction-in-pancreatic-cancer","Current Advances in Preclinical Patient-Derived Cultivation Models for Individualized Drug Response Prediction in Pancreatic Cancer","","Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, with low overall survival despite multimodal therapy, and current biomarkers still fail to predict treatment response reliably in vivo. This review addresses the clinical gap by focusing on tumor microenvironment effects and intratumoral heterogeneity that drive resistance. It summarizes in vivo and ex vivo patient-derived cultivation models for PDAC and evaluates how these platforms may support treatment response prediction and clinical translation through individualized biological criteria.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-advances-in-preclinical-patient-derived-cultivation-models-for-individualized-drug-response-prediction-in-pancreatic-cancer/354082/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-advances-in-preclinical-patient-derived-cultivation-models-for-individualized-drug-response-prediction-in-pancreatic-cancer/354082.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is individualized drug response prediction difficult in pancreatic cancer patients?","Question",{"text":112,"@type":113},"Despite advances in molecular profiling, identified biomarkers do not yet enable sufficient in vivo prediction. Limited survival and heterogeneous tumor biology, including tumor microenvironment effects and intratumoral heterogeneity, contribute to treatment resistance and hinder accurate stratification.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What clinical problem does this review highlight regarding PDAC therapy?",{"text":117,"@type":113},"There is an unmet clinical need for preclinical cultivation models that can predict treatment response based on individual biological features. High drug attrition in trials is attributed to inadequate and overly artificial models that neglect tumor microenvironment complexity.",{"name":119,"@type":110,"acceptedAnswer":120},"Which patient-derived cultivation model types are discussed for treatment response prediction?",{"text":121,"@type":113},"The review covers in vivo patient-derived xenografts and ex vivo systems including organoids, organotypic slice cultures, and cancer-on-chip models, emphasizing their potential for integrating multiple tissue components relevant to PDAC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354082,1790241217,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Tech Science Press  \n[https://doi. org/10.32604/or.2026.075028](https://doi. org/10.32604/or.2026.075028)  \nREVIEW  \nCurrent Advances in Preclinical Patient-Derived Cultivation Models for Individualized Drug Response Prediction in Pancreatic Cancer  \nBenjamin Heckelmann\\#, Jannis Duhn\\# and Rüdiger Braun*  \nDepartment of Surgery, University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, Lübeck, Germany  \n*Corresponding Author: Rüdiger Braun. Email: [ruediger.braun@uksh.de](ruediger.braun@uksh.de)  \n\\# These authors contributed equally to this work  \nReceived: 23 October 2025; Accepted: 30 January 2026; Published: 22 April 2026  \nABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cancer-related cause of death worldwide and is forecasted to become the second leading cause in the United States by 2030 . Despite the development of multimodal treatment regimens, 5-year overall survival remained as low as 12% . Several efforts have been made to account for different aspects of heterogeneous tumor biology in PDAC, aiming to enable treatment stratification of defined subtypes. Besides targeting specific mutations, the definition of molecular (transcriptional) subtypes has gained substantial interest regarding response prediction and treatment stratification. Despite numerous advances in the field of genomic, transcriptomic, and proteomic characterization, the identified biomarkers do not yet facilitate predicting treatment response sufficiently in patients in vivo. Considering the growing evidence on the impact of the tumor microenvironment (TME) and intratumoral heterogeneity (ITH) on treatment resistance, there is an unmet clinical need for preclinical cultivation models that allow for predicting treatment response based on individual biological criteria. This review discusses the current advances in such in vivo (patient-derived xenografts) and ex vivo (organoids, organotypic slice cultures, cancer-on-chip) models for treatment response prediction and stratification in PDAC, and their potential implications in clinical translation.  \nKEYWORDS: Pancreatic cancer; precision oncology; patient-derived xenografts; patient-derived organoids; organotypic slice cultures; cancer-on-chip  \n1 Introduction  \nPancreatic ductal adenocarcinoma (PDAC) is currently the third leading cancer-related cause of death worldwide and is forecasted to become the second leading cause in the United States by 2030 [1,2] . Once having been diagnosed, radical surgical resection followed by conventional chemotherapy remains the only curative treatment-option for PDAC patients. However, due to long asymptomatic or unspecific courses, only about 10%–15% of the patients are diagnosed in an early stage, amenable to primary resection [2,3] .  \nIn recent years, the introduction of polychemotherapy regimens, such as modified FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin), improved the survival of patients from 6.8 to 11.1 months in the metastatic setting and from 35 to 54.4 months in the adjuvant resected setting, compared to gemcitabine monotherapy in large phase-III studies [4,5] . However, despite the introduction of these regimens into clinical guidelines, 5-year overall survival remained as low as 12%[2] . The reasons for the limited survival of pancreatic cancer patients are diverse. A recent cross-validation study of national German  \nCopyright © 2026 The Authors. Published by Tech Science Press. This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nand American cancer registries has shown that only about 54% of all patients achieved the goal of guidelineconform therapy, so-called textbook outcome [6] . The selection of (neo)adjuvant treatment regimens, mFOLFIRINOX or gemcitabine (with nab-paclitaxel), is mainly based on the patien","cbCair6UTESCzYjB","https://ap.wps.com/l/cbCair6UTESCzYjB","pdf",7743699,27,"English","# Introduction\n## Clinical need and limitations of current biomarkers\n## Rationale for patient-derived cultivation models\n## Patient-derived xenografts and microenvironment constraints\n## Advanced TME-integrated models (organoids, slice cultures, cancer-on-chip)","[{\"question\":\"Why is individualized drug response prediction difficult in pancreatic cancer patients?\",\"answer\":\"Despite advances in molecular profiling, identified biomarkers do not yet enable sufficient in vivo prediction. Limited survival and heterogeneous tumor biology, including tumor microenvironment effects and intratumoral heterogeneity, contribute to treatment resistance and hinder accurate stratification.\"},{\"question\":\"What clinical problem does this review highlight regarding PDAC therapy?\",\"answer\":\"There is an unmet clinical need for preclinical cultivation models that can predict treatment response based on individual biological features. High drug attrition in trials is attributed to inadequate and overly artificial models that neglect tumor microenvironment complexity.\"},{\"question\":\"Which patient-derived cultivation model types are discussed for treatment response prediction?\",\"answer\":\"The review covers in vivo patient-derived xenografts and ex vivo systems including organoids, organotypic slice cultures, and cancer-on-chip models, emphasizing their potential for integrating multiple tissue components relevant to PDAC.\"}]","Current Advances in Preclinical Patient-Derived Cultivation Models for Individualized Drug Response Prediction in Pancreatic Cancer | PDF",1790108806,68,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/049ed1fab926fab8cbfddd1cad16555e.webp",983,1271,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1e02fd9d349bcefc10bed3683ed92c4.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13cebbc0496666efe0337de21bfebd3e.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f1e57d2b8dba08ffff787a1671bf8af.webp",980,1267]